Valantine Hannah sold $342K of BBIO

Valantine Hannah sold 5,004 shares of BridgeBio Pharma, Inc. (BBIO) at an average of $68.25 ($68.00–$68.57, $0.34M total) across 2 trades over 2026-06-22 to 2026-06-23 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Valantine Hannah
Published Jun 24, 2026, 10:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 24, 2026, 10:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BBIO
Neutral
medium confidence
Mentioned
$BBIO
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BBIONeutralLow
01

Why it matters

The disclosed event is an open-market sale by a director under a pre-arranged 10b5-1 plan; absent other news, it mainly informs positioning/sentiment rather than fundamentals.

02

Market read

Traders may note the insider selling signal, but the 10b5-1 structure and lack of new business catalysts suggest limited impact.

03

What to watch

The article provides only the sale details; it does not include any offsetting buys, broader insider activity context, or changes in company guidance/operations.

Relevance 3/10Novelty 3/10Timing: after-hours/filing timestamp (2026-06-24) for today’s Form 4 disclosure

Background

The article is a primary-source SEC Form 4 insider transaction for BridgeBio Pharma, Inc. (BBIO).

Company-level read

Ticker impact

$BBIONeutralMedium confidence
Context

BridgeBio Pharma director Valantine Hannah sold $341.5K of BBIO shares via an open-market sale under a 10b5-1 plan (Form 4 filed today).

Expected impact

Likely minimal immediate price impact; any effect would be sentiment-driven and short-lived.

Evidence & confidence

The filing discloses a routine, pre-arranged 10b5-1 sale with modest size relative to typical large-cap float, and no accompanying operational/regulatory catalyst is provided.

Market effects

No sector read-through; this is a single-company insider transaction with no new clinical/regulatory datapoints.

None indicated.

None indicated.

Counterpoint

Even 10b5-1 sales can coincide with private information or portfolio rebalancing; traders may still fade/trim risk if multiple insiders sell.

Key entities

  • BridgeBio Pharma, Inc.

    Subject of the Form 4 insider transaction; director Valantine Hannah sold shares under a 10b5-1 plan.

  • Valantine Hannah

    Director who executed two open-market sale trades totaling $341,523.72.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LLYMed

Global Gene Therapy for Hearing Loss Market Report 2026 | Capture Growth to $1.71B by 2030 as Regeneron, Lilly, Sensorion and Astellas Advance AAV, CRISPR and Cochlear Delivery

The global gene therapy for hearing loss market is projected to reach $1.71B by 2030, with companies like Regeneron, Lilly, Sensorion, and Astellas focusing on AAV and CRISPR therapies. Regeneron's Otarmeni received FDA approval in 2026, and acquisitions, such as Regeneron's $109M purchase of Decibel Therapeutics, are shaping the market. North America leads, but Asia-Pacific is expected to grow rapidly.

$INOHighAI 9/10

KXCO's FDA ontology ranked INO-3107 first. After the approval, Inovio (INO) traded over 300% higher after hours. Three more FDA decisions are on our radar.

Inovio Pharmaceuticals (INO) received FDA approval for its drug VOCERYQ (INO-3107), leading to a 351.7% after-hours trading surge and a 215.0% gain in the next session. KXCO's AI ontology predicted this outcome. Three other FDA decisions are upcoming for BridgeBio (BBIO), Cogent (COGT), and Praxis (PRAX).

$BBIOMed

BridgeBio Pharma Earnings Call Signals Multi-Drug Breakout

BridgeBio Pharma (BBIO) reported Q3 earnings with $353.2M revenue, up from $120.7M YoY, driven by Attruby sales. The company highlighted three potential drug launches within seven months and a $1.5B cash position. Management expects continued revenue growth and narrowing losses, with Attruby on track to meet or exceed $4B peak sales.

$BBIOMedAI 8/10

BridgeBio (BBIO) Q3 2026 Earnings Call Transcript

BridgeBio (BBIO) reported Q3 2026 earnings, with Attruby's U.S. net product revenue at $253.2 million, up 14% quarter-on-quarter and 134% year-over-year. The company expects Attruby to meet or exceed $4 billion in peak year sales and sees similar potential in three other brands. Management highlighted strong performance among cardiologists and plans to target a broader range of prescribers. Positive real-world evidence and kidney protective signals were also discussed.

$BBIOMed

BridgeBio Pharma Inc (BBIO) (Q3 2026) Earnings Call Highlights: Attruby Surge Drives Record

BridgeBio Pharma (BBIO) reported a $31M sequential increase in Attruby revenue, with executives forecasting continued growth. The company expects $25M-$30M in near-term revenue and $1.5B cash to cover operational needs. Attruby's market share is driven by real-world evidence and renal protective data. The company anticipates an average operating loss of $90M-$100M per quarter in 2026, improving from 2025.